Literature DB >> 2289199

Selective restoration of immunosuppressive effect of cytotoxic agents by thymopoietin fragments.

L Dénes1, B Szende, G Hajós, L Szporny, K Lapis.   

Abstract

Swiss male mice were immunosuppressed by cyclophosphamide, cisplatinum, vincristine and methotrexate. The ability of the thymopoietin (TP) fragments TP-3, TP-4 and TP-5 to restore antibody production and phagocytosis was studied. Impaired antibody production after vincristine treatment was partially or totally restored by TP-3, TP-4 or TP-5. Only TP-3 or TP-5 interfered with the antibody-production-damaging effect of cisplatinum. The same effect of methotrexate could not be influenced by any of the TP fragments. The phagocytic capacity of peritoneal macrophages was reduced by vincristine, methotrexate and cyclophosphamide treatment. In this respect, TP-3 protected the function of macrophages against vincristine and cyclophosphamide treatment. TP-4 was active in the case of damage caused by vincristine and methotrexate, and TP-5 interfered with the phagocytosis-inhibiting effect of methotrexate. Each TP fragment seems to have a specific target orientation within the immune system. This also means that the proper TP fragment should always be chosen for combination therapy with various types of cytotoxic drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2289199     DOI: 10.1007/bf01741724

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

1.  The antigenic structure of influenza virus as studied by a simple immune serum absorption test.

Authors:  G TAKATSY; J FURESZ
Journal:  Acta Microbiol Acad Sci Hung       Date:  1954

2.  Immunoregulating peptides II. In vitro effects of TP5 analogs on E-rosette formation and cell division.

Authors:  L Denes; B Szende; J Ember; J Major; L Szporny; G Hajos; O Nyeki; I Schon; K Lapis; L Kisfaludy
Journal:  Immunopharmacol Immunotoxicol       Date:  1987       Impact factor: 2.730

3.  The influence of new thymopoietin derivatives on the immune response of inbred mice.

Authors:  E Rajnavölgyi; J Kulics; M Szilágyvári; L Kisfaludy; O Nyéki; I Schön; J Gergely
Journal:  Int J Immunopharmacol       Date:  1986

4.  Differential chemotherapeutic susceptibility of human T-lymphocytes and B-lymphocytes in culture.

Authors:  T Ohnuma; H Arkin; J Minowada; J F Holland
Journal:  J Natl Cancer Inst       Date:  1978-04       Impact factor: 13.506

5.  Dose-survival curves of cis-platinum, melphalan, and velban in human granulocyte/macrophage progenitor cells.

Authors:  G E Umbach; S E Singletary; B Tomasovic; G Spitzer; V Hug; B Drewinko
Journal:  Int J Cell Cloning       Date:  1984-11

6.  Immunoregulation by thymopoietin.

Authors:  G Goldstein; C Y Lau
Journal:  J Supramol Struct       Date:  1980

7.  Restoration of diminished T-cell function in adjuvant induced disease by methotrexate: evidence for two populations of splenic T-cell suppressors.

Authors:  L Kourounakis; M A Kapusta
Journal:  J Rheumatol       Date:  1976-12       Impact factor: 4.666

8.  Therapeutic possibilities of thymopoietin fragments (TP3 and TP4) based on experimental animal models.

Authors:  L Dénes; B Szende; G Hajós; L Szporny; K Lapis
Journal:  Drugs Exp Clin Res       Date:  1987

9.  Loss of monocyte membrane receptors in patients with SLE.

Authors:  M Kávai; K Lukács; I Sonkoly; I J Jókay; A Berndt; G Szegedi
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

View more
  2 in total

Review 1.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.

Authors:  A D Garg; E Romano; N Rufo; P Agostinis
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

2.  Adult mouse kidneys become permissive to acute polyomavirus infection and reactivate persistent infections in response to cellular damage and regeneration.

Authors:  I A Atencio; F F Shadan; X J Zhou; N D Vaziri; L P Villarreal
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.